Replies to post #186005 on Biotech Values

[DewDiligence]

RVNC appoints senior R&D executive at SHPG to BoD:

http://finance.yahoo.com/news/revance-appoints-dr-philip-vickers-220000463.html

Revance Therapeutics, Inc., a specialty biopharmaceutical company developing botulinum toxin products for use in aesthetic and therapeutic indications, today announced that Philip J. Vickers, Ph.D., Executive Vice President and Global Head of Research & Development at Shire plc, has been appointed to its Board of Directors, effective February 26, 2015.

Curious.

[DewDiligence]

RVNC had $171M of cash at 12/31/14—2015 cash-burn guidance of $74-84M unchanged from JPM conference in January:

http://finance.yahoo.com/news/revance-therapeutics-releases-fourth-quarter-210500437.html